Skip to main content
. 2020 Dec 5;75(4):e13849. doi: 10.1111/ijcp.13849

FIGURE 1.

FIGURE 1

HCRU outcomes at baseline and aggregate 12‐month period by sildenafil‐P use. Total visits for any reason: physician/nurse practitioner visits and pharmacist visits. Total visits for cardiologists, CVD check‐ups and sexual functioning discussions. Baseline and total visits over 12 months variables reflect a 12‐month recall period. For physician/nurse practitioner and pharmacist visits for any reason, n = 1,162 participants provided data for all timepoints. For cardiologist and CVD check‐up visits, n = 282 participants provided data for all time points. For pharmacist visits for sexual functioning discussions, n = 107 participants provided data for all timepoints. Error bars depict 95% confidence intervals. CVD, cardiovascular disease; sildenafil‐P, pharmacy medicine sildenafil.